Ponatinib: Off-label use followed by acquired drug resistance: case report

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661321/
http://dx.doi.org/10.1007/s40278-021-07205-x
_version_ 1784613343499124736
collection PubMed
description
format Online
Article
Text
id pubmed-8661321
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-86613212021-12-10 Ponatinib: Off-label use followed by acquired drug resistance: case report Reactions Weekly Case Report Springer International Publishing 2021-12-11 2021 /pmc/articles/PMC8661321/ http://dx.doi.org/10.1007/s40278-021-07205-x Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Ponatinib: Off-label use followed by acquired drug resistance: case report
title Ponatinib: Off-label use followed by acquired drug resistance: case report
title_full Ponatinib: Off-label use followed by acquired drug resistance: case report
title_fullStr Ponatinib: Off-label use followed by acquired drug resistance: case report
title_full_unstemmed Ponatinib: Off-label use followed by acquired drug resistance: case report
title_short Ponatinib: Off-label use followed by acquired drug resistance: case report
title_sort ponatinib: off-label use followed by acquired drug resistance: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661321/
http://dx.doi.org/10.1007/s40278-021-07205-x

Ejemplares similares